Skip to main content

Nuclear Medicine

ANSTO's Lucas Heights Precinct in Sydney is home to three key facilities that enable Australia's advanced manufacturing and distribution of nuclear medicines.


Our nuclear medicine team recently attended the 54th annual scientific meeting of the Australian and New Zealand Society of Nuclear Medicine. 

Nuclear medicine and your health

Nuclear medicine and your health

Every Australian is likely to benefit from nuclear medicine and on average will have at least two nuclear medicine procedures in their lifetime.

About 75-80 per cent of nuclear medicine isotopes used in Australia come from ANSTO. We partner with nuclear medicine professionals to enable 700,000[1] patient procedures each year[2].

Learn about nuclear medicine and your health

Medicine production

Take a look at how Molybdenum-99 (Mo-99), the most widely used nuclear medicine in the world, is manufactured at ANSTO. 

Mo-99 is produced in the ANSTO's OPAL nuclear reactor, processed at the Mo-99 Manufacturing Facility and despatched to practitioners in shielded Gentech® Generators.

See video

On average, ANSTO’s radioisotopes provide 10,000-12,000 nuclear medicine procedures that benefit Australians each week[1].

Clinical trials

Lutetium-177: Prostate cancer and melanoma

ANSTO is the supplier of non-carrier added (n.c.a) Lutetium-177 (Lu-177) used in prostate cancer and melanoma clinical trials being undertaken by ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre and Melanoma & Skin Cancer Trials.

Follow the journey

Every Australian is likely to benefit from nuclear medicine and, on average, will have at least two nuclear medicine procedures in their lifetime[1]

See how nuclear medicine makes its way from ANSTO's OPAL reactor to medical centres around Australia.

View video

News & Innovation

ANSTO researchers are continuously working to develop new nuclear medicines to help fight diseases, including cancer, by using our comprehensive science kit and radiochemicals.


[1] based on published Medicare statistics combined with non-MBS data sourced from the nuclear medicine community:

[2] These include diagnostic imaging scans (SPECT and PET) to aid in patient management and a growing range of therapies.

Ask us a question

If you would like to place a product order or have any further questions please contact the Health team.